Abstract Library

#3265 Assessment of hormonal levels as prognostic markers and of their optimal cut-offs in small intestinal neuroendocrine tumors grade 2

Introduction: Multianalytes might be used to monitor small intestinal neuroendocrine tumors (siNETs) Grade 2 in the future, but blood chromogranin A (CgA) and urine 5HIAA are still widely used in clinical praxis.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Papantoniou D, Grönberg M, Landerholm K, Welin S, Ziolkowska B,

Keywords: Chromogranin A, 5HIAA, small intestinal neuroendocrine tumor, biomarker, carcinoid, cut-offs,

#2104 Direct Cost of Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Grade 1 or 2 (G1/G2) in Relation to Time Since Diagnosis Shows Growing Importance of Somatostatin Analogues (SSA)

Introduction: Metastatic GEP-NET G1/G2 incurs large costs on the Swedish health care system.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Berthon A

Authors: Berthon A, Granfeldt D, Björstad A, Marlow T, Dinét J,

Keywords: metastatic, GEP-NET, cost-of-illness, somatostatin analogues,

#1842 OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET).

Introduction: OPALINE Study focuses on patients with pNET. Two targeted therapies (TT) offer new options to treat these patients: mTORi (everolimus) and a multi-targeted inhibitor (sunitinib).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lombard-Bohas V

Authors: Lombard-Bohas C, Lepage C, Vicaut E, Dominguez S, Coriat R,

Keywords: pNET, targeted therapy,

#151 Rationale for combining mTOR with other targeted agents in the treatment of neuroendocrine tumors

Introduction: Advanced neuroendocrine tumors (NETs) are aggressive and incurable with standard treatment. Many cellular targets are being evaluated in this patient population, including mammalian target of rapamycin (mTOR), a kinase that is the central regulator of several signaling pathways related to cell growth, angiogenesis, and bioenergetics. Because mTOR serves as a neoplastic switch activated by many cancer-related mutations, mTOR inhibition may have broad efficacy across tumor types, including NETs. Somatostatin analogs (SSAs) have long been used to treat carcinoid symptoms in NET patients. The SSA octreotide long-acting release (LAR) demonstrated significant antitumor effects against advanced midgut NETs in the phase III PROMID study.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Öberg K, Yao J,

Keywords: neuroendocrine tumors, mammalian target of rapamycin, somatostatin analogs, vascular endothelial growth factor, cytotoxic therapy, interferon-alpha, controlled clinical trials,